Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 2.39
ITMN's Cash to Debt is ranked lower than
71% of the 830 Companies
in the Global Biotechnology industry.

( Industry Median: 56.40 vs. ITMN: 2.39 )
ITMN' s 10-Year Cash to Debt Range
Min: 0.65   Max: No Debt
Current: 2.39

Equity to Asset 0.53
ITMN's Equity to Asset is ranked lower than
65% of the 600 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. ITMN: 0.53 )
ITMN' s 10-Year Equity to Asset Range
Min: -0.92   Max: 0.98
Current: 0.53

-0.92
0.98
F-Score: 4
Z-Score: 12.56
M-Score: -1.27
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -188.88
ITMN's Operating margin (%) is ranked lower than
60% of the 649 Companies
in the Global Biotechnology industry.

( Industry Median: -75.73 vs. ITMN: -188.88 )
ITMN' s 10-Year Operating margin (%) Range
Min: -2967.17   Max: 48.26
Current: -188.88

-2967.17
48.26
Net-margin (%) -207.91
ITMN's Net-margin (%) is ranked lower than
62% of the 649 Companies
in the Global Biotechnology industry.

( Industry Median: -71.50 vs. ITMN: -207.91 )
ITMN' s 10-Year Net-margin (%) Range
Min: -2862.47   Max: 51.15
Current: -207.91

-2862.47
51.15
ROE (%) -108.21
ITMN's ROE (%) is ranked lower than
84% of the 754 Companies
in the Global Biotechnology industry.

( Industry Median: -27.51 vs. ITMN: -108.21 )
ITMN' s 10-Year ROE (%) Range
Min: -218.91   Max: 562.64
Current: -108.21

-218.91
562.64
ROA (%) -43.66
ITMN's ROA (%) is ranked lower than
66% of the 832 Companies
in the Global Biotechnology industry.

( Industry Median: -23.16 vs. ITMN: -43.66 )
ITMN' s 10-Year ROA (%) Range
Min: -80.98   Max: 58.29
Current: -43.66

-80.98
58.29
ROC (Joel Greenblatt) (%) -4593.93
ITMN's ROC (Joel Greenblatt) (%) is ranked lower than
79% of the 805 Companies
in the Global Biotechnology industry.

( Industry Median: -344.23 vs. ITMN: -4593.93 )
ITMN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -8945.36   Max: 5020.96
Current: -4593.93

-8945.36
5020.96
Revenue Growth (3Y)(%) -39.60
ITMN's Revenue Growth (3Y)(%) is ranked lower than
81% of the 396 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. ITMN: -39.60 )
ITMN' s 10-Year Revenue Growth (3Y)(%) Range
Min: -58.3   Max: 91.6
Current: -39.6

-58.3
91.6
» ITMN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

ITMN Guru Trades in Q1 2014

Steven Cohen 7,637 sh (New)
Chuck Royce 328,000 sh (New)
PRIMECAP Management 6,627,500 sh (+2.40%)
Columbia Wanger 1,120,800 sh (-57.09%)
» More
Q2 2014

ITMN Guru Trades in Q2 2014

Joel Greenblatt 6,487 sh (New)
Jim Simons 426,129 sh (New)
Steven Cohen 240,600 sh (unchged)
Columbia Wanger Sold Out
Chuck Royce 278,000 sh (-15.24%)
PRIMECAP Management 4,525,925 sh (-31.71%)
» More
Q3 2014

ITMN Guru Trades in Q3 2014

Mario Gabelli 60,000 sh (New)
Joel Greenblatt Sold Out
Chuck Royce Sold Out
Jim Simons Sold Out
PRIMECAP Management Sold Out
Steven Cohen Sold Out
» More
Q4 2014

ITMN Guru Trades in Q4 2014

Mario Gabelli Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ITMN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on InterMune Inc

Mario Gabelli Comments on InterMune Inc - Oct 28, 2014

InterMune Inc. (ITMN) is a California based biotechnology company focused on the research, development, and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases. On August 24, 2014, InterMune received a $74 cash per share tender offer from Swiss pharmaceuticals company Roche Holding AG, valuing the company at $8.3 billion. The offer was conditioned on tender acceptance of a majority of InterMune’s outstanding shares. The offer successfully concluded on September 29, 2014. The Fund earned a 13.2% return.

From Mario Gabelli (Trades, Portfolio)’s ABC Fund Q3 2014 Commentary.

Check out Mario Gabelli latest stock trades

Top Ranked Articles about InterMune Inc

Mario Gabelli Comments on InterMune Inc
InterMune Inc. (ITMN) is a California based biotechnology company focused on the research, development, and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases. On August 24, 2014, InterMune received a $74 cash per share tender offer from Swiss pharmaceuticals company Roche Holding AG, valuing the company at $8.3 billion. The offer was conditioned on tender acceptance of a majority of InterMune’s outstanding shares. The offer successfully concluded on September 29, 2014. The Fund earned a 13.2% return. Read more...

Ratios

vs
industry
vs
history
Forward P/E 181.82
ITMN's Forward P/E is ranked lower than
97% of the 182 Companies
in the Global Biotechnology industry.

( Industry Median: 22.17 vs. ITMN: 181.82 )
N/A
P/B 22.39
ITMN's P/B is ranked lower than
138% of the 713 Companies
in the Global Biotechnology industry.

( Industry Median: 3.32 vs. ITMN: 22.39 )
ITMN' s 10-Year P/B Range
Min: 2.98   Max: 27.19
Current: 22.39

2.98
27.19
P/S 60.07
ITMN's P/S is ranked lower than
116% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: 7.28 vs. ITMN: 60.07 )
ITMN' s 10-Year P/S Range
Min: 2.19   Max: 109.71
Current: 60.07

2.19
109.71
Current Ratio 6.99
ITMN's Current Ratio is ranked higher than
63% of the 805 Companies
in the Global Biotechnology industry.

( Industry Median: 4.36 vs. ITMN: 6.99 )
ITMN' s 10-Year Current Ratio Range
Min: 1.08   Max: 52.48
Current: 6.99

1.08
52.48
Quick Ratio 6.87
ITMN's Quick Ratio is ranked higher than
64% of the 805 Companies
in the Global Biotechnology industry.

( Industry Median: 4.07 vs. ITMN: 6.87 )
ITMN' s 10-Year Quick Ratio Range
Min: 1.07   Max: 52.34
Current: 6.87

1.07
52.34
Days Inventory 256.67
ITMN's Days Inventory is ranked lower than
82% of the 404 Companies
in the Global Biotechnology industry.

( Industry Median: 115.80 vs. ITMN: 256.67 )
ITMN' s 10-Year Days Inventory Range
Min: 49.87   Max: 956.76
Current: 256.67

49.87
956.76
Days Sales Outstanding 101.61
ITMN's Days Sales Outstanding is ranked lower than
72% of the 556 Companies
in the Global Biotechnology industry.

( Industry Median: 61.41 vs. ITMN: 101.61 )
ITMN' s 10-Year Days Sales Outstanding Range
Min: 2.61   Max: 254.09
Current: 101.61

2.61
254.09

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) -2.80
ITMN's Earnings Yield (Greenblatt) is ranked higher than
60% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: -4.40 vs. ITMN: -2.80 )
ITMN' s 10-Year Earnings Yield (Greenblatt) Range
Min: -2.8   Max: 13.5
Current: -2.8

-2.8
13.5

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:IUX.Germany,
InterMune, Inc was incorporated in California in 1998 and reincorporated in Delaware in 2000 in connection with its initial public offering. InterMune is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases. The Company's business is mainly focused on the development and commercialization of therapies within the specialized areas of pulmonology and orphan fibrotic diseases. It has an advanced-stage product candidate in pulmonology, pirfenidone that was granted marketing authorization effective February 2011 in all 27 member countries of the European Union for the treatment of adults with mild to moderate idiopathic pulmonary fibrosis. Pirfenidone is an orally active, small molecule compound under development for the treatment of idiopathic pulmonary fibrosis. Pirfenidone, a treatment for IPF, a progressive and fatal lung disease, has completed the global Phase 3 CAPACITY clinical development program. Actimmune is currently approved in the United States for the treatment of chronic granulomatous disease and severe, malignant osteopetrosis. Actimmune is also approved for commercial use in both indications in numerous other countries. CGD is a life-threatening congenital disorder that causes patients, mainly children, to be vulnerable to severe, recurrent bacterial and fungal infections. This results in frequent and prolonged hospitalizations and commonly results in death. Severe, malignant osteopetrosis is a life-threatening, congenital disorder that mainly affects children. This disease results in increased susceptibility to infection and an overgrowth of bony structures that might lead to blindness and/or deafness. The FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries impose substantial requirements upon the clinical development, manufacture and marketing of pharmaceutical products.
» More Articles for ITMN

Headlines

Articles On GuruFocus.com
Mario Gabelli Comments on InterMune Inc Oct 28 2014 
Roche to Acquire InterMune and Deliver Hope to Patients Worldwide Aug 25 2014 
How Sanofi's Growth Strategy Will Catapult Afrezza Into a Blockbuster Drug Aug 20 2014 
Weekly CEO Sells Highlight: Protective Life Corp, Western Refining Inc, InterMune Inc, and Tableau S Aug 18 2014 
Weekly Insider Sells Highlight: BX, PCYC, MAS, ITMN Mar 03 2014 
11 Mar 07 2012 
WEEKLY CFO SELLS HIGHLIGHT: ITMN, DISCA, WEC, EMAN, WTW, CAH May 22 2011 
InterMune Inc. (ITMN) Chairman, CEO and President Daniel G Welch sells 44,000 Shares Mar 04 2011 
InterMune Inc. Reports Operating Results (10-Q) Nov 08 2010 
InterMune Inc. Reports Operating Results (10-Q) Aug 09 2010 

More From Other Websites
After big sale to Roche, InterMune boss jumps to venture capital Jan 08 2015
Goldman Sachs beats earnings estimates Oct 16 2014
Roche, Boehringer Drugs Wins Approval for Lung Disease Oct 15 2014
INTERMUNE INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of... Sep 29 2014
Roche purchases shares in tender offer for InterMune, Inc. Sep 29 2014
InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action Sep 19 2014
Roche's $8 billion InterMune buy not a signal for more big deals Sep 16 2014
[video] Cramer: ACAD and ISIS have room to run Sep 11 2014
INTERMUNE INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Sep 05 2014
InterMune Announces Anticipated Fundamental Change for 5.00% Convertible Senior Notes Due 2015 Sep 05 2014
Lifshitz & Miller Law Firm Announces Investigation of China Housing & Land Development, Inc., Cobra... Sep 02 2014
What You Need to Know About the Roche-InterMune Deal Aug 29 2014
Cramer: Sector could be hotbed of 'bolt-on' deals Aug 28 2014
InterMune drug may offer big upside to Roche if aimed at liver Aug 27 2014
InterMune Stockholders Encouraged to Contact Securities Law Firm about Takeover Aug 27 2014
INTERMUNE SHAREHOLDER ALERT – InterMune, Inc.: The Law Offices of Vincent Wong Investigates the... Aug 27 2014
INTERMUNE INVESTOR ALERT: Faruqi & Faruqi, LLP is Investigating the Board of Directors of InterMune,... Aug 27 2014
Roche, InterMune a Strategic Play in Midst of Inversions Aug 27 2014
The Zacks Analyst Blog Highlights: Roche, InterMune, Achillion Pharmaceuticals, Puma Biotechnology... Aug 27 2014
INVESTOR ALERT – InterMune, Inc.: The Law Offices of Vincent Wong Investigates the Sale of... Aug 26 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK